AstraZeneca introduced SGLT-2 inhibitor based diabetes treatment 'Dapaglifozin' in the market

Published: 2014-03-21 14:20:09

Updated: 2014-03-21 14:20:09

On Mar 19, AstraZeneca prepared the place in Westin Chosun Seoul, to introduce SGLT-2 inhibitor based diabetes treatment 'Dapaglifozin' which got the nation's first approval from Ministry of Food and Drug Safety.

Dapagliflozin is a SGLT-2 inhibitor. It blocks SGLT-2 receptors in urine which are involved in glucose uptake so that the remaining glucose is excreted in the urine. As glucose in the...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.